Bringing VISION to Nuclear Medicine: accelerating evidence and changing paradigms with theranostics.

Abstract

I first became excited about prostate-specific membrane antigen (PSMA) as a game-changing target for nuclear medicine at the 2011 European Association of Nuclear Medicine meeting in Birmingham. The target had been identified 2 decades beforehand ([ 1 ][1],[ 2 ][2]). A new approach using radiolabeled